SG11201811023UA - Small molecule modulators of pantothenate kinases - Google Patents
Small molecule modulators of pantothenate kinasesInfo
- Publication number
- SG11201811023UA SG11201811023UA SG11201811023UA SG11201811023UA SG11201811023UA SG 11201811023U A SG11201811023U A SG 11201811023UA SG 11201811023U A SG11201811023U A SG 11201811023UA SG 11201811023U A SG11201811023U A SG 11201811023UA SG 11201811023U A SG11201811023U A SG 11201811023UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cove
- pct
- rule
- pantothenate
- Prior art date
Links
- 108010021592 Pantothenate kinase Proteins 0.000 title 1
- 102100024122 Pantothenate kinase 1 Human genes 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662354012P | 2016-06-23 | 2016-06-23 | |
PCT/US2017/039037 WO2017223474A1 (en) | 2016-06-23 | 2017-06-23 | Small molecule modulators of pantothenate kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811023UA true SG11201811023UA (en) | 2019-01-30 |
Family
ID=60783428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811023UA SG11201811023UA (en) | 2016-06-23 | 2017-06-23 | Small molecule modulators of pantothenate kinases |
Country Status (15)
Country | Link |
---|---|
US (2) | US10899734B2 (ko) |
EP (1) | EP3474667A4 (ko) |
JP (1) | JP7078555B2 (ko) |
KR (1) | KR102459256B1 (ko) |
CN (1) | CN109561680B (ko) |
AU (1) | AU2017281907B2 (ko) |
BR (1) | BR112018076441A2 (ko) |
CA (1) | CA3025260A1 (ko) |
DO (1) | DOP2018000293A (ko) |
IL (1) | IL263649B (ko) |
MX (1) | MX2018015170A (ko) |
SA (1) | SA518400696B1 (ko) |
SG (1) | SG11201811023UA (ko) |
WO (1) | WO2017223474A1 (ko) |
ZA (1) | ZA201808099B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7078555B2 (ja) | 2016-06-23 | 2022-05-31 | セント ジュード チルドレンズ リサーチ ホスピタル,インコーポレイティド | パントテン酸キナーゼの小分子調節剤 |
AU2018395222B2 (en) * | 2017-12-27 | 2023-06-08 | Coa Therapeutics, Inc. | Small molecule modulators of pantothenate kinases |
CN111787939A (zh) * | 2017-12-27 | 2020-10-16 | 圣朱德儿童研究医院有限公司 | 治疗castor相关疾病的方法 |
EP3825303A4 (en) * | 2018-07-17 | 2022-07-06 | Nippon Chemiphar Co., Ltd. | T-CALCIUM CHANNEL BLOCKERS |
CA3135011A1 (en) * | 2019-03-27 | 2020-10-01 | St. Jude Children's Research Hospital | Small molecule modulators of pank |
AU2020250468A1 (en) * | 2019-03-29 | 2021-11-04 | Kinki University | Use of T-type calcium channel blocker for treating pruritus |
JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用 |
US20240116892A1 (en) * | 2022-08-08 | 2024-04-11 | Ajax Therapeutics, Inc. | Heterocyclic amide and urea compounds as jak2 inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6894063B2 (en) | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
US20020165223A1 (en) * | 2000-09-14 | 2002-11-07 | Greenlee William J. | Substituted urea neuropeptide Y Y5 receptor antagonists |
US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
US7582635B2 (en) * | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
MY142655A (en) * | 2003-06-12 | 2010-12-15 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
JP4831577B2 (ja) * | 2003-07-30 | 2011-12-07 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピリダジン誘導体および治療剤としての用途 |
US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
US20060035884A1 (en) | 2004-05-20 | 2006-02-16 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
EP2089018A2 (en) | 2006-11-07 | 2009-08-19 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
AU2008269128B2 (en) | 2007-06-25 | 2012-08-02 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
AU2012280420B2 (en) | 2011-07-01 | 2017-01-05 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
AR091023A1 (es) * | 2012-05-11 | 2014-12-30 | Abbvie Inc | Inhibidores del nampt |
TW201444821A (zh) * | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
US10273228B2 (en) | 2015-04-17 | 2019-04-30 | Indiana University Research And Technology Corporation | Hepatitis B viral assembly effectors |
JP7078555B2 (ja) | 2016-06-23 | 2022-05-31 | セント ジュード チルドレンズ リサーチ ホスピタル,インコーポレイティド | パントテン酸キナーゼの小分子調節剤 |
-
2017
- 2017-06-23 JP JP2018566834A patent/JP7078555B2/ja active Active
- 2017-06-23 US US16/307,473 patent/US10899734B2/en active Active
- 2017-06-23 WO PCT/US2017/039037 patent/WO2017223474A1/en unknown
- 2017-06-23 AU AU2017281907A patent/AU2017281907B2/en active Active
- 2017-06-23 KR KR1020197000671A patent/KR102459256B1/ko active IP Right Grant
- 2017-06-23 SG SG11201811023UA patent/SG11201811023UA/en unknown
- 2017-06-23 EP EP17816310.1A patent/EP3474667A4/en active Pending
- 2017-06-23 BR BR112018076441-8A patent/BR112018076441A2/pt unknown
- 2017-06-23 CA CA3025260A patent/CA3025260A1/en active Pending
- 2017-06-23 MX MX2018015170A patent/MX2018015170A/es unknown
- 2017-06-23 CN CN201780043423.3A patent/CN109561680B/zh active Active
-
2018
- 2018-11-29 ZA ZA2018/08099A patent/ZA201808099B/en unknown
- 2018-12-11 IL IL263649A patent/IL263649B/en unknown
- 2018-12-19 SA SA518400696A patent/SA518400696B1/ar unknown
- 2018-12-21 DO DO2018000293A patent/DOP2018000293A/es unknown
-
2020
- 2020-12-14 US US17/120,800 patent/US20210246113A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3474667A1 (en) | 2019-05-01 |
WO2017223474A1 (en) | 2017-12-28 |
US10899734B2 (en) | 2021-01-26 |
IL263649A (en) | 2019-01-31 |
CN109561680A (zh) | 2019-04-02 |
CN109561680B (zh) | 2021-07-13 |
RU2019101613A (ru) | 2020-07-23 |
RU2019101613A3 (ko) | 2020-12-03 |
US20190300499A1 (en) | 2019-10-03 |
AU2017281907B2 (en) | 2021-10-21 |
EP3474667A4 (en) | 2019-11-27 |
DOP2018000293A (es) | 2019-04-15 |
MX2018015170A (es) | 2019-07-04 |
BR112018076441A2 (pt) | 2019-04-09 |
JP7078555B2 (ja) | 2022-05-31 |
KR102459256B1 (ko) | 2022-10-25 |
SA518400696B1 (ar) | 2023-01-09 |
CA3025260A1 (en) | 2017-12-28 |
ZA201808099B (en) | 2019-07-31 |
IL263649B (en) | 2022-04-01 |
AU2017281907A1 (en) | 2019-01-03 |
US20210246113A1 (en) | 2021-08-12 |
JP2019518764A (ja) | 2019-07-04 |
KR20190022620A (ko) | 2019-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811023UA (en) | Small molecule modulators of pantothenate kinases | |
SG11201909777YA (en) | Modulatory polynucleotides | |
SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201808528VA (en) | Modified wound dressings | |
SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201809643UA (en) | Compositions and methods of treating huntington's disease | |
SG11201805118XA (en) | Solid fluorescence standard | |
SG11201809276QA (en) | N-((heteroarylmethyl)-heteroaryl-carboxamide derivatives as plasma kallikrein inhibitors | |
SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
SG11201408174UA (en) | Antibody formulation | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
SG11201803230RA (en) | Needle devices with adjustable grips and related methods | |
SG11201910015SA (en) | Gene therapy for neuronal ceroid lipofuscinoses | |
SG11201909837YA (en) | Methods for treating lung disorders |